TransMedics Group (NASDAQ:TMDX) Posts Quarterly Earnings Results, Misses Expectations By $0.32 EPS

TransMedics Group (NASDAQ:TMDX) posted its quarterly earnings data on Tuesday. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32), FiscalAI reports. The company had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 24.01%. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period last year, the business earned $0.70 EPS.

Here are the key takeaways from TransMedics Group’s conference call:

• Q1 results were strong — revenue was $174 million (≈21% YoY, 8% sequential), adjusted operating profit was ~$18.1M (~10% margin), and the company ended the quarter with ~$462M in cash.
• CHOPS and clinical path forward — TransMedics unveiled CHOPS as a regulated cold‑storage device that will serve as the control arm for ENHANCE/DENOVO; an IDE supplement will be filed in weeks with approval and implementation expected in early Q3 2026 and a later 510(k) for commercial use planned.
• Major product and geographic expansion — the company is advancing OCS Kidney on its Gen 3.0 platform (final design shown late June; targeting a U.S. IDE in early 2027), upgrading heart/lung/liver to Gen 3.0, and building a European NOP/logistics network via a PAD Aviation partnership to expand TAM.
• Revenue outlook reiterated — management reaffirmed full‑year 2026 revenue guidance of $727M–$757M (20%–25% growth), citing continued OCS/NOP volume and international expansion as drivers.
• Near‑term margin and enrollment risks — gross margin fell to ~58% (down ~331 bps YoY) and adjusted operating expenses rose ~42% YoY as the company is heavily investing in R&D, NOP expansion and supply‑chain inventory; additionally, donor volumes remain volatile amid U.S. transplant modernization, which could pressure near‑term growth and margins.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $72.92 on Thursday. TransMedics Group has a fifty-two week low of $70.00 and a fifty-two week high of $156.00. The business has a 50-day simple moving average of $115.33 and a two-hundred day simple moving average of $125.66. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of 16.57 and a beta of 2.07.

Key Headlines Impacting TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Q1 revenue grew ~21% year-over-year driven by strong OCS demand, showing continued top-line momentum that supports longer-term growth expectations. TransMedics Reports First Quarter 2026 Financial Results
• Positive Sentiment: Several firms remain constructive on upside even after cuts — Needham, TD Cowen, Piper Sandler and Canaccord lowered targets but maintained buy/overweight stances (targets now in the ~$120–$142 range, Canaccord to $124). Those calls keep a path for sizable upside if execution rebounds. Needham Price Target Lowered
• Neutral Sentiment: FY2026 revenue guidance was issued in a range ($727M–$757M) that overlaps Street expectations, leaving uncertainty — guidance isn’t a clear beat or miss and leaves room for interpretation on pacing. TransMedics FY2026 Guidance (Slide Deck)
• Negative Sentiment: Q1 EPS missed badly: $0.30 vs. consensus ~$0.62 — the big earnings shortfall and margin compression are the primary near-term negative catalyst. TransMedics tumbles after earnings miss
• Negative Sentiment: Analysts reacted: Oppenheimer downgraded TMDX from Outperform to Market Perform, and Stifel cut its target sharply to $85 and moved to Hold — these downgrades tighten near-term selling pressure. Oppenheimer Downgrade Stifel Price Target Cut
• Negative Sentiment: Market commentary highlights valuation risk — at least one independent write-up argues the stock still prices near-perfect execution and remains a sell despite recent weakness. That narrative can deter buyers until clearer execution/lift in margins is visible. Valuation critique — still priced for perfection
• Negative Sentiment: Coverage updates included multiple target trims (TD Cowen, Piper Sandler among others) which, even when keeping buy ratings, lower the valuation anchor and reduce conviction near term. TD Cowen Price Target Cut

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Piper Sandler cut their target price on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a research note on Wednesday. Needham & Company LLC lowered their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday. Stifel Nicolaus cut their price objective on shares of TransMedics Group from $130.00 to $85.00 and set a “hold” rating on the stock in a research report on Wednesday. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, TD Cowen decreased their target price on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $135.00.

Insider Activity

In other news, insider Nicholas Corcoran sold 2,966 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $412,629.92. Following the sale, the insider owned 29,831 shares of the company’s stock, valued at $4,150,088.72. This trade represents a 9.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Anil P. Ranganath sold 864 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $120,199.68. Following the transaction, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. The trade was a 6.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 16,205 shares of company stock worth $2,353,002. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently added to or reduced their stakes in the stock. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group in the 3rd quarter worth $29,000. Allworth Financial LP increased its position in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Parallel Advisors LLC increased its position in TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after acquiring an additional 83 shares during the last quarter. US Bancorp DE lifted its holdings in TransMedics Group by 24.2% in the third quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after acquiring an additional 104 shares during the period. Finally, Atlas Capital Advisors Inc. bought a new position in TransMedics Group in the fourth quarter valued at about $61,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.